We are pleased to announce that we have launched our 22nd Annual Report this week at the annual congress for the British Orthopaedic Association. The aim of the NJR Annual Report is to increase the availability of evidence-based information in joint replacement surgery to all NJR stakeholders by providing a year-on-year view of clinical activity and outcomes. The report also provides a summary of the work and progress of the registry including management and funding. The full published report, along with associated appendices, infographics and updates on NJR activity and committees can be found on the NJR’s dedicated Annual Report website.
Having collected data since April 2003, with the purpose of improving patient outcomes following hip, knee, ankle, elbow, and shoulder replacement, the registry has now recorded over 4.5 million procedures. Everyone with an interest in joint replacement will be delighted to see that we show even more widespread and up-to-date analyses of the outcomes of the many implant brands available.
As a result of the increasing volume and quality of data, it is possible to make more accurate analysis available to all stakeholders. It is essential that as much good quality data as possible is captured to continue to improve clinical outcomes and patient safety – the report has also been prepared in separate joint sections again this year. A key message is that patient safety and clinical outcomes continue to improve, as identified through the year-on-year reduction of joint revision surgery.
Annual Clinical Reports (ACR’s) for hospitals are also now available on NJR Connect. You can log in to find your ACR here
These reports show NJR data for the most recent complete financial year and cover:
- Indicators of data quality: rates of compliance, patient consent and linkability.
- Hip and knee replacement outcomes data (funnel plots), for revision for all hospitals and surgeons (anonymised), across procedure types.
- Hospital outcomes data for hip and knee replacement (funnel plots) for mortality.